Frost & Sullivan
As patents for key blockbuster drugs begin to expire and plant use begins to wane, experts are looking to Europe for a boom in contract manufacturing.
With blockbuster drugs coming off patent, there will be lots of excess manufacturing capacity in Europe, and that could provide a chance for contract manufacturers to expand there.
One of the big trends in pharma outsourcing in recent years has been a move to contracting out manufacturing services. Frost & Sullivan picked up on that trend in a recent market view, plotting...